Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 2092-2100

  Ninomiya, Soranobu ^a   Shimizu, Masahito ^a   Imai, Kenji ^a   Takai, Koji ^a   Shiraki, Makoto ^a   Hara, Takeshi ^a   Tsurumi, Hisashi ^a   Ishizaki, Sonoko ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AJINOMOTO CO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BRANCHED CHAIN AMINO ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN KINASE B;

AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

AMINO ACIDS, BRANCHED-CHAIN; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 83055174653     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0340     Document Type: Article

References (42)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
2. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80. (Pubitemid 43343895)
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
4. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006;35:204-14.
5. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651-61.
6. Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Bustos M, Martinez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78.
7. Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, et al. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res 2010;40:911-22.
8. Watanabe N, Takai K, Imai K, Shimizu M, Naiki T, Nagaki M, et al. Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. J Clin Biochem Nutr In press 2011.
9. Chen C, Chang YC, Liu CL, Liu TP, Chang KJ, Guo IC. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 2007; 14:513-29. (Pubitemid 47242649)
10. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-7.
11. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6. (Pubitemid 47008083)
12. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/ obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515-27.
13. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17.
14. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
15. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damas JK, et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:3039-47.
16. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010;10:119-25.
17. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006;55:285-91. (Pubitemid 43117290)
18. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, Hoogenboom HR, et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 2002;101:118-27. (Pubitemid 34970903)
19. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101:1286-91.
20. Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, et al. Anovel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010;31:51-7.
21. Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, et al. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells 2010;30:341-5.
22. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42. (Pubitemid 37413486)
23. Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. Biochem Biophys Res Commun 2004;313:405-9. (Pubitemid 37543600)
24. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005;3:705-13. (Pubitemid 40984733)
25. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 2010;101: 460-7.
26. Shimizu M, Shirakami Y, Iwasa J, Shiraki M, Yasuda Y, Hata K, et al. Supplementation with branched-chain amino acids inhibits azoxymethane- induced colonic preneoplastic lesions in male C57BL/KsJ-db/ db mice. Clin Cancer Res 2009;15:3068-75.
27. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989;19: 98-129.
28. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009;285:210-7.
29. Kitagawa J, Hara T, Tsurumi H, Ninomiya S, Ogawa K, Adachi S, et al. Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2. J Cancer Res Clin Oncol 2011;137: 779-87.
30. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-14.
31. Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J, et al. Nicotinamide phosphoribosyltransferase (NAMPT/ PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010;391:376-81.
32. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-65. (Pubitemid 351556097)
33. Kim JY, Bae YH, Bae MK, Kim SR, Park HJ, Wee HJ, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta 2009;1793:1759-67.
34. Shimizu M, Sakai H, Shirakami Y, Iwasa J, Yasuda Y, Kubota M, et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice. Cancer Prev Res 2011;4:128-36.
35. Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, Terakura D, et al. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine- induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/ db mice. Cancer Prev Res 2011;4:396-403.
36. She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, et al. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 2007;6:181-94. (Pubitemid 47324140)
37. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008;22:105-12.
38. Arakawa M, Masaki T, Nishimura J, Seike M, Yoshimatsu H. The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. Endocr J 2011;58:161-70.
39. Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, et al. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44:483-91.
40. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009;273:194-200.
41. Desbois-Mouthon C, Blivet-Van Eggelpoël MJ, Beurel E, Boissan M, Delélo R, Cadoret A, et al. Dysregulation of glycogen synthase kinase- 3beta signaling in hepatocellular carcinoma cells. Hepatology 2002; 36:1528-36.
42. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res 2010;40:376-82.